Presenters
The University of Chicago Medicine
George Bakris, MD, Hon. DSc, FASN, FAHA
Course Details
Cardiovascular disease is a continuum and patients with multiple cardiovascular risk factors need cardioprotection to prevent the occurrence of myocardial infarction, stroke, hospitalization for heart failure or cardiovascular death. In this webinar, Professor George Bakris (Illinois, USA) discussed the ONTARGET clinical trial programme, which evaluated the efficacy of telmisartan in preventing these outcomes in high CV-risk patients. He also outlined the renal benefits of this ARB and their supporting clinical evidence.
Estimated time of Completion: 28 mins. and 32 secs.
CPD Points: 0.5 Point
PRC Program No: PROG-2023-59937
Role of Telmisartan in Hypertension in People with High CV Risk-Course Outline
- Cardiovascular disease in patients with or without chronic kidney disease
- Lower eGFR is Associated with Cardiovascular Events and Death
- Studies Investigating Effects of RAAS Manipulation on CV Disease Outcomes
- Heart Outcomes Prevention Evaluation (HOPE) Study
- The PROTECTION Programme
- The ONTARGET/TRANSCEND Trial Programme: study design
- ONTARGET: Telmisartan is As Effective As Ramipril in Preventing CV Events at Increased CV Risk
- Renal-ONTARGET: Renal outcome (dialysis and doubling of s-creatinine)
- TRANSCEND: Trial Design
- Approach to BP Therapy
- Best Proven Nonpharmacologic Interventions for Prevention and Treatment of Hypertension
- Initial Combinations of Medications
- ESC/ESH 2018
- 2020 Philippine Hypertension CPG
- Causes of Poor BP control
- Does Combining a Beta Blocker with a RAS inhibitor have additive BP Effects?
- ARBs: Are they all created equal?
- Receptor Binding affinity relative to half life
- Affinity and potency of ARBs at AT1 receptors
- Telmisartan Community Access Trial (MICCAT II)
- Novel Agents Being Developed for Resistant Hypertension
PC-PH-104932 / June 2023